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INTRODUCTION
The cycle of respiratory tract infection (RTI) and inflammation in patients with chronic obstructive 
lung diseases, such as cystic fibrosis (CF), periodically develops into exacerbations, where 
chronic colonization of the airway by bacteria causes severe decline in lung function, leading 
to increased hospitalization and high mortality rates (1, 2). Current antibiotic inhalation treat-
ments approved for the management of chronic airway infections in cystic fibrosis are limited 
to tobramycin (TOBI®) and more recently, aztreonam (Cayston®). A major drawback to these 
localized treatments of RTIs is the rapid absorption and clearance of antibiotics from the lungs 
requiring multiple daily inhalations of high concentration antibiotic solutions. Hence, liposomal 
ciprofloxacin nanoparticles were developed to prolong lung residence time of the antibiotics, with 
the view to enhance antimicrobial activity and reduce the burden of therapy for the patients and 
their relatives who often have to assist them. Although in vivo studies with aerosolized delivery 
of liposomal ciprofloxacin have previously been performed on human and animal subjects, in vitro 
cell models may be better suited to study the transport, interactions of drugs and carrier systems, 
and drug localization within and on the airway cell epithelium at a molecular level. Therefore, the 
aim of this study was to investigate the newly developed system allowing nebulized liposomal cip-
rofloxacin to be delivered directly to the bronchial epithelial surface in an established air interface 
Calu-3 cell model. 
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MATERIALS AND METHODS
Two nebulized ciprofloxacin formulations: Liposomal ciprofloxacin (CFI) and free ciprofloxacin 
(FCI) aqueous systems were analysed in terms of their release profiles and antimicrobial efficacy, 
using in vitro methodologies. The formulations were prepared as previously described (3). Briefly, 
the CFI was prepared by actively loading ciprofloxacin into ~90 nm unilamellar vesicles via a 
transmembrane pH gradient generated in response to an ammonium sulphate gradient. 
Calu-3, a bronchial epithelial cell line, was seeded at a density of 5 X 105 cells/cm2 on 
Transwell polyester inserts (Corning Costar, USA). The cells were grown at the air-interface to 
allow for monolayer differentiation and cell polarization. Experiments were performed between 
day 11 and 14 in culture (4). The formulations were aerosolized, using a Pari LC Sprint® nebulizer, 
directly onto the Calu-3 bronchial epithelia cells placed in Stage 2 of an in vitro twin-stage impinger 
(TSI; Copley Scientific, Nottingham, UK) to assess the release kinetics. Two milliliters of diluted 
CFI and FCI was introduced into the reservoir of the nebulizer and was aerosolized for 5 seconds 
at a flow rate of 15 L/min, allowing <20 μg of ciprofloxacin to be deposited onto the Calu-3 cells. 
Samples were taken at pre-determined time points for up to 4 hours post treatment and cells were 
washed gently with Hank’s Balanced Salt Solution (HBSS) (Invitrogen, Australia) at the final time 
point to collect the remaining drug on the cell monolayer. Cells were subsequently lysed to release 
and quantify intracellular drug. Samples were analyzed using high-performance liquid chromatog-
raphy (HPLC). Confocal live cell imaging (LSM 510 Microscope Meta, Carl Zeiss, Australia) was 
also performed after deposition of the formulation on the Calu-3 cells with 10X objective and UV 
laser (405nm) at various time points. 
The antibacterial activities of the formulations were compared by determining the minimum 
bactericidal concentrations (MBC) on Pseudomonas aeruginosa (NCTC7244). Prior to MBC deter-
mination, the minimum inhibitory concentration (MIC) was established using a standard twofold 
serial dilution method with cation-adjusted Mueller-Hinton broth (CAMHB), according to 
National Committee for Clinical Laboratory Standards (NCCLS) guidelines (5). The drug con-
centration used ranged from 32 to 0.153 μg/mL. The MBC was subsequently determined by sampling 
100 μL from each MIC broth dilution that lacked visible growth, and inoculating on blood agar 
which was finally incubated at 37°C for 24 hours. The bactericidal endpoint for MBC was defined 
as the drug concentration that demonstrated a reduction of ≥ 99.9% of the initial inoculum.
RESULTS AND DISCUSSION
The release kinetics of CFI and FCI formulations are shown in Figure 1. CFI effectively 
controlled the release of ciprofloxacin, with approximately 1.5% of the drug being transported across 
the epithelial over 4 hours. In comparison, the FCI formulation showed >33% of the drug trans-
ported over the same time period. No effects were observed on the epithelial cell integrity following 
exposure to either formulations or control, as there was no statistical differences in transepithelial 
electrical resistance observed. 
The quantitative analysis was further confirmed by confocal imaging, where CFI showed 
slow diffusional spreading of the deposited aerosols into the surrounding epithelial lining fluid 
after 4 hours. In comparison, the FCI diffuses and spreads rapidly into the epithelial lining fluid 
giving a relatively even antibiotic distribution of antibiotics within 30 minutes. The FCI was hardly 
detected on the cell surface after 1.5 hours (images not shown). These results are in qualitative 
agreement with animal and human pharmacokinetic data; in healthy subjects and in patients, the 
terminal plasma half-life of ciprofloxacin inhaled in the form of CFI was ~10 hours which is much 
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longer than the terminal plasma half-life following IV or oral administration of ciprofloxacin or 
inhalation of unencapsulated ciprofloxacin (3, 6, 7). Thus, the different transport kinetics, distribu-
tion and interaction with the lung epithelium of the ciprofloxacin formulations were observed in 
the air-interfaced Calu-3 cell and impactor system providing a qualitatively representative assess-
ment of release and transport kinetics with respect to in vivo conditions.
 
Figure 1. Release profile of nebulized liposomal ciprofloxacin (CFI) (n=6, mean ±S.D, SD<1.5%) and free 
ciprofloxacin (FCI) (n=6, mean ±SD) formulations on Calu-3 air interface model. 
The in vitro antimicrobial activities of the ciprofloxacin formulations on laboratory strain 
P. aeruginosa are shown in Table 1. The MBC value for CFI was found to be significantly lower 
compared to the FCI. It is hypothesized that the enhanced antimicrobial activity against P. aerugi-
nosa is due to the fusion of the phospholipids of liposomes with the bacterial outer membrane (8). 
In addition, the increased retention time of ciprofloxacin in the lungs would further enhance the 
antimicrobial efficacy of the formulation in vivo.
Table 1.
In vitro antimicrobial activity of nebulized liposomal ciprofloxacin (CFI) and  
free ciprofloxacin (FCI) against Pseudomonas aeruginosa.
CONCLUSIONS
Inhaled formulations of liposomal ciprofloxacin are a promising treatment for pulmonary infections. 
The use of the combined TSI and Calu-3 air-interface model for the assessment of transport 
rate after drug deposition from nebulizer could be an attractive model to potentially reduce much 
animal and human experimentation. The combined TSI and Calu-3 air-interface model requires 
further refinements to more closely approximate in vivo transport rates.
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